Is there any reason to switch endocrine therapy after a patient undergoes bilateral oophorectomy?  

This patient is a young lady with stage IV ER/PR positive, Her2 negative with oligometastatic  breast cancer undergoing a planned bilateral oopherectomy due to an ovarian cyst and elevated CA 125.  She is currently on tamoxifen and tolerating it well. Is there any data to suggest the patient should be switched to an AI or can be otherwise maintained on tamoxifen?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Medical College of Wisconsin
In addition, With Tamoxifen (until disease progre...
Sign in or Register to read more